Medical Solutions

Leukomed® Sorbact®

Leukomed Sorbact: an innovative post-operative film dressing to help reduce wound bacteria colonisation by its physical mode of action.

Explore below to find out more about Leukomed Sorbact, the clinical evidence supporting its use and the impact it may have on Surgical Site Infection (SSI) rates and patient quality of life.

Clinical information

Leukomed Sorbact’s mode of action and clinical evidence.


Find out more

Maternity

Leukomed Sorbact and caesarean section wounds.


Find out more

Vascular

Leukomed Sorbact and vascular surgery.


Find out more

Tissue Viability

Leukomed Sorbact’s role in preventing SSI and managing post-operative wounds.


Find out more

Infection Control

Leukomed Sorbact and SSI risk reduction.


Find out more

Procurement

Potential cost savings from Leukomed Sorbact.


Find out more

NICE Guidance

New NICE medical technologies guidance for Leukomed Sorbact.


Find out more

*© NICE 2021 Leukomed Sorbact for preventing surgical site infection. Available from

www.nice.org.uk/guidance/mtg55. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Contact